Idorsia Ltd. · SIX:IDIA
Idorsia — Idorsia Pharmaceuticals — H1 2020 Earnings Presentation
19 slides from Idorsia's earnings presentation, Jul 23, 2020
Slide 1: Half Year 2020 Financial Reporting
Financial Reporting 20 HALF YEAR 20
Slide 2: Forward-looking statements
The following information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”,
Slide 3: CEO quote: positive daridorexant results
“The highlight in the first half of 2020 is the positive daridorexant results – we are now preparing to file with the US FDA around the end of this year.” Jean-Paul Clozel Chief Executive Officer 3 Half Year 2020 Financial Reporting | 23 Jul 2020
Slide 4: Half year highlights
Positive pivotal results with 20 HALF YEAR daridorexant 20 License agreement with Neurocrine Janssen submitted Issuance of 11 million NDA and EMA for new shares raises ponesimod CHF 330 million 4 Half Year 2020 Financial Reporting | 23 Jul 2020
Slide 5: Clinical development pipeline
Clinical development pipeline Compound Mechanism of Action Target Indication Status Daridorexant Dual orexin receptor antagonist Insomnia Filing in preparation Aprocitentan* Dual endothelin receptor antagonist Resistant hypertension management Phase 3 Vasospasm associated with aneurysmal Clazosentan
Slide 6: Our Strategic Priorities
Our Strategic Priorities Our mid-term key priorities to 2 Build and integrate a commercial organization achieve long-term 3 Bring Idorsia to success: sustainable profitability 1 Deliver at least three products to market 4 Create a pipeline with a sales potential of CHF 5 billion 5 Utilize state-of-t
Slide 7: Daridorexant – Pivotal program
Daridorexant – Pivotal program The program with daridorexant demonstrated statistically significant and clinically meaningful improvements at month 1 and at month 3 Efficacy during the night and the day Safety and tolerability profile consistent between both pivotal studies Sleep • No dose-dependent
Slide 8: CCO quote: moving at full power with daridorexant
“We are moving at full power following the outstanding results with daridorexant.” Simon Jose Chief Commercial Officer 8 Half Year 2020 Financial Reporting | 23 Jul 2020
Slide 9: Insomnia impacts millions of people during the night and the day
Insomnia impacts millions of people during the night and the day ≥ 3 nights/week • Estimated 20 million1 adults in the US suffer ≥ 3 months from chronic insomnia Difficulty staying asleep • Insomnia has a significant impact on patients’ productivity, quality of life and long-term Difficulty falling
Slide 10: High unmet need for effective, safe medications
High unmet need for effective, safe medications US prescription insomnia market Quarterly Standard units (millions)1 • Decline in z-drug prescriptions since FDA dose change & safety FDA black-box warning for complex FDA issued warnings in 2013 900 warnings for z-drugs sleep behavior on z-drugs 80% u
Slide 11: Preparing for a successful launch
Preparing for a successful launch Opportunity to Potential to improve transform and sleep and daytime Disruptive Differentiated modernize performance without insomnia market compromising safety Strong regional Simple, efficient partners to reach Smart approach to building Nimble broad primary partne
Slide 12: CFO quote: lower than expected OPEX
“Cost-control and the COVID-19 pandemic have resulted in lower than expected OPEX.” André C. Muller Chief Financial Officer 12 Half Year 2020 Financial Reporting | 23 Jul 2020
Slide 13: US GAAP net results
US GAAP net results 20 FIRST HALF in CHF millions, rounding differences may occur 20 Non-GAAP US GAAP Financial results as of June 30, 2020 13 Half Year 2020 Financial Reporting | 23 Jul 2020
Slide 14: Non-GAAP operating expenses
Non-GAAP operating expenses 20 FIRST HALF in CHF millions, rounding differences may occur 20 -5 -7 0 -9 -56 -49 -23 -26 -101 -151 -193 -234 1H 2019 1H 2020 Research Development Selling G&A Milestones Non-GAAP operating expenses Financial results as of June 30, 2020 14 Half Year 2020 Financial Report
Slide 15: Cash flow
Cash flow 20 FIRST HALF in CHF millions, rounding differences may occur 20 Financial results as of June 30, 2020 15 Half Year 2020 Financial Reporting | 23 Jul 2020
Slide 16: Liquidity
Liquidity 20 FIRST HALF in CHF millions, rounding differences may occur 20 908 908 180 146 Cash deposits Other FX > 12 months 348 Cash deposits USD < 12 months 750 Cash and CHF Cash equivalents 380 Liquidity @ Liquidity @ Jun 30, 2020 Jun 30, 2020 Financial results as of June 30, 2020 16 Half Year 2
Slide 17: Financial Guidance for 2020
Financial Guidance + + + 20 for 2020 ++ + FIRST HALF 20 US GAAP operating expenses around CHF 530 million and non-GAAP operating expenses around CHF 490 million Both measures exclude unforeseen events, potential milestone payments and any potential award granted in the ongoing arbitration 17 Half Ye
Slide 18: Stay tuned!
Stay tuned! “The second half of 2020 promises to be every bit as exciting as the first.” Jean-Paul Clozel Chief Executive Officer 18 Half Year 2020 Financial Reporting | 23 Jul 2020
Slide 19: Our Strategic Priorities
Our Strategic Priorities Our mid-term key priorities to 2 Build and integrate a commercial organization achieve long-term 3 Bring Idorsia to success: sustainable profitability 1 Deliver at least three products to market 4 Create a pipeline with a sales potential of CHF 5 billion 5 Utilize state-of-t
Idorsia Pharmaceuticals — H1 2020 Earnings Presentation on 6ix